The Math Shows FYC Can Go To $71 Tuesday, May 23, 7:20 AM ET, by Market News Video Staff Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...
Noteworthy Thursday Option Activity: VRDN, AA, UPST Thursday, June 22, 3:24 PM ET, by Market News Video Staff Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume ...
The Implied Analyst 12-Month Target For VHT Monday, July 24, 8:33 AM ET, by Market News Video Staff Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...
Commit To Purchase Viridian Therapeutics At $12.50, Earn 37% Annualized Using Options
By Market News Video Staff, Friday, March 15, 11:51 AM ET
Investors considering a purchase of Viridian Therapeutics Inc (NASDAQ:VRDN) shares, but cautious about paying the going market price of $17.24/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $12.50 strike, which has a bid at the time of this writing of $2.75. Collecting that bid as the premium represents a 22% return against the $12.50 commitment, or a 37% annualized rate of return (at Stock Options Channel we call this the YieldBoost).
Selling a put does not give an investor access to VRDN's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $12.50 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Viridian Therapeutics Inc sees its shares fall 27.7% and the contract is exercised (resulting in a cost basis of $9.75 per share before broker commissions, subtracting the $2.75 from $12.50), the only upside to the put seller is from collecting that premium for the 37% annualized rate of return.
Below is a chart showing the trailing twelve month trading history for Viridian Therapeutics Inc, and highlighting in green where the $12.50 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the October put at the $12.50 strike for the 37% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Viridian Therapeutics Inc (considering the last 251 trading day closing values as well as today's price of $17.24) to be 61%. For other put options contract ideas at the various different available expirations, visit the VRDN Stock Options page of StockOptionsChannel.com.
In mid-afternoon trading on Friday, the put volume among S&P 500 components was 829,525 contracts, with call volume at 829,525, for a put:call ratio of 0.72 so far for the day, which is above normal compared to the long-term median put:call ratio of .65. In other words, if we look at the number of call buyers and then use the long-term median to project the number of put buyers we'd expect to see, we're actually seeing more put buyers than expected out there in options trading so far today.
Find out which 15 call and put options traders are talking about today.
This Article's Word Cloud:OctoberOptionsStockTherapeuticsVRDNViridianYieldBoostaboutaboveamongannualizedbenefitbuyerscallchartconsideringcontractexercisedfillColorfromgoinghistorylongmarketmedianmonthnumberonlyoptionsotherowningpremiumpricerateratiorepresentsreturnsellersellingsharesharesstriketermthanthatthistodaytradingwhichwith
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?
⤹
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.